Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaContact: Tammy KnightTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT05047198
- Record updated
- 30 September 2026
- Original description
This study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows investigators to identify ventricular tachycardia circuits to target for subsequent radio ablation. To summarize, the current standard of care invasive catheter ablation to the non-invasive radio ablation.Read full original descriptionShow less
This study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows investigators to identify ventricular tachycardia circuits to target for subsequent radio ablation. To summarize, the current standard of care invasive catheter ablation to the non-invasive radio ablation.
Inclusion: Patient aged ≥55 years of age; Cardiomyopathy (Left ventricular ejection fraction ≤ 35% and ICD in situ) AND; Recurrent VT events despite previous CA OR; VT events requiring intervention and PAINESD score ≥ 15.
Exclusion: Patients who have previously received thoracic radiotherapy; Patients with NYHA Class IV heart failure \&/ or with LVAD in situ; Patients aged ≤54 years of age; Pregnancy (all women of child bearing age and potential will have a negative β-HCG test before enrollment); Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception (IUD, sterilization, birth control implant or birth control pill) throughout the study; Patients not expected to live for more than one year for any reason; Patients who are enrolled in another randomized clinical trial; Patients who are unable or unwilling to provide informed consent; Breastfeeding.